Ross Bray

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet · 2021 · 560 citations

Once-daily Insulin Degludec, Metabolic Syndrome, Diabetes Management +11

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

Dominik Dahl, Yukiko Onishi, Paul Norwood et al. · JAMA · 2022 · 512 citations · Full text

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó et al. · The Lancet Diabetes & Endocrinology · 2022 · 429 citations

Obesity, Metabolic Syndrome, Body Composition +12

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman, Arun J. Sanyal, Rohit Loomba et al. · Diabetes Care · 2020 · 321 citations · Full text

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Melissa K. Thomas, Amir Nikooienejad, Ross Bray et al. · The Journal of Clinical Endocrinology & Metabolism · 2020 · 300 citations · Full text